Market Overview

UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, Platform

Related CPHD
UPDATE: ISI Group Upgrades Cepheid
Cepheid Posts Narrower-than-Expected Q2 Loss, Revenues Rise

Bank of America initiated coverage on Cepheid (NASDAQ: CPHD) with a Buy rating and a $40 price objective.

Bank of America noted, "With one of the largest available test menus and more on the way, CPHD's prospects for increasing its installed base and reagent pull-through is positive, as it will become increasingly difficult for customers to justify supporting multiple platforms that run a limited number of tests. As more labs convert to MDx testing, we see CPHD as well positioned to grow. Moreover, our checks suggest that CPHD should see some success as it engages the MDx heavyweights in more established segments of the market (eg, CT/NG)."

Cepheid closed at $32.63 on Friday.

Latest Ratings for CPHD

DateFirmActionFromTo
Sep 2014Cantor FitzgeraldUpgradesHoldBuy
Aug 2014ISI GroupUpgradesSellNeutral
Jul 2014Raymond JamesMaintainsOutperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (CPHD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters